甘精胰岛素市场:各类型(甘精胰岛素)，各地区(北美，欧洲，亚太地区，中东·非洲，南美)-规模，占有率，展望，机会分析，2022年～2028年

Insulin Glargine Market, By Type (Insulin Glargine) and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日期: 2022年09月20日 | 出版商:

Coherent Market Insights | 英文 167 Pages | 商品交期: 2-3个工作天内

价格

简介目录

市场力学。

糖尿病患病率的增加、老年人口的增加、临床试验数量的增加、研发的增加以及公众意识的提高是预计将有助于全球甘精胰岛素市场增长的一些主要因素。

本调查的主要特征

本报告提供以2021年为基准年的预测期间（2022-2030 年）之全球甘精胰岛素市场的市场规模和復合年增长率（CAGR %）相关的详细分析。
并阐明不同部门市场的潜在收入机会，说明该市场具有魅力的投资主张矩阵。
同时并提供市场推动因素和限制、机会、新产品发布或批准、市场趋势、区域前景和主要参与者采用的竞争战略等重要考察。
并基于企业亮点，各类型投资组合、主要焦点、财务业绩和市场策略等参数，介绍全球甘精胰岛素市场的主要参与者之企业简介。
藉由该报告提供的洞察，将能帮助营销人员和公司高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
全球甘精胰岛素市场报告配合该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
利益相关者可以透过全球甘精胰岛素市场用于分析的各种战略矩阵来帮助他们更容易做下决策。

Insulin glargine is a long-acting, synthetic version of human insulin. It belongs to a drug class called long-acting insulins. It is a form of medical insulin used to manage type I and type II diabetes. Like other types of insulin, insulin glargine is used to keep blood sugar level close to normal. It works by replacing the insulin that is produced by the body and by helping move sugar from the blood into other body tissues where it is used for the energy. Insulin glargine is FDA approved to treat adults and children with type 1 diabetes and adults with type 2 diabetes. Thus, there is an increase in demand for insulin glargine worldwide.

Market Dynamics:

Increase in prevalence of diabetes, growing geriatric population, increase in number of clinical trials, increase in research and development, and increase in awareness among people are some major factors expected to aid in the growth of the global insulin glargine market.

In January 2022, FDA announced its approval of Rezvoglar (insulin glargine-aglr), a new long-acting basal insulin, for adults and children with type 1 diabetes and adults with type 2 diabetes. Rezvoglar was approved as a biosimilar to Sanofi's Lantus (insulin glargine).

In December 2021, FDA approved a second insulin glargine biosimilar, an Eli Lilly product called Rezvoglar, which references Lantus.

In June 2020, Biocon and Mylan got the U.S. food and drug administration nod to launch for its insulin glargine injection in vial and pre-filled pen presentations, to control high blood sugar in adults with type 2 diabetes and adult and pediatric patients with type 1 diabetes.

Key features of the study:

This report provides in-depth analysis of the global insulin glargine market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global insulin glargine market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Julphar, Biocon, Eli Lilly, Sanofi Aventis, and Novo Nordisk AS, among others.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global insulin glargine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global insulin glargine market.

Detailed Segmentation:

Global Insulin Glargine Market By Type:
- Insulin Glargine
Global Insulin Glargine Market By Geography:
- North America
- Europe
- Asia-Pacific
- Middle East and Africa
- South America
Company Profiles:
- Julphar
- Biocon
- Eli Lilly
- Sanofi Aventis
- Novo Nordisk AS

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
Middle East and Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
Rest of World
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)

7. Competitive Landscape

Julphar
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Biocon
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi Aventis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novo Nordisk AS
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Analyst Views